JNJ stock trades at $239 as of June 11, 2026, and we rate it a Buy — the risk/reward favours bulls even with shares just 5% below the 52-week high of $251.71. Johnson & Johnson has returned roughly 60% from its 52-week low of $149.04, raised its dividend for a 64th consecutive year, and lifted full-year 2026 guidance to roughly $100.8 billion in revenue. The first mention of the JNJ stock price in any serious 2026 healthcare discussion now comes with a different tone than a year ago: this is no longer a defensive laggard, it is a new-product growth story.
This JNJ stock price analysis covers valuation, the bullish and bearish analyst opinions shaping Wall Street’s targets, the June 2026 Firefly Bio acquisition, and a clear verdict. The headline numbers first:
| Key Stock Data | Value (June 11, 2026) |
|---|---|
| Current Price | ~$239 |
| 52-Week Range | $149.04 – $251.71 |
| Market Cap | ~$570 billion |
| P/E Ratio (trailing / forward) | 22x / 21x |
| EPS (FY2026 guidance, adjusted) | $11.30 – $11.50 |
| Dividend | $5.36/yr (64th straight increase) |
| Analyst Consensus | Buy / Moderate Buy |
| Average Price Target | $238 – $253 (high: $280) |
Table of Contents
- JNJ Stock Key Takeaways
- What Is Johnson & Johnson? (NYSE: JNJ)
- JNJ Stock Recent Performance in 2026
- JNJ Stock Valuation Analysis
- JNJ Dividend and Income Profile
- Bullish and Bearish Analyst Opinions on Johnson & Johnson
- JNJ Stock Analyst Price Targets and Verdict
- JNJ Stock Risks to Watch Through 2026
- How to Trade JNJ Stock via MEXC
- JNJ Stock FAQs
JNJ Stock Key Takeaways
- Price and verdict: JNJ stock trades near $239 with a Buy rating; consensus targets cluster between $238 and $253, with HSBC’s Street-high at $280 implying roughly 17% upside.
- Key stat: Q1 2026 revenue hit $24.06 billion (vs. $23.61 billion expected) with EPS of $2.70, and management raised full-year guidance to ~$100.8 billion in sales — operational growth of 5.9% to 6.9%.
- Bull case: New launches Icotyde (oral IL-23, launched April 2026) and Inlexzo, plus Darzalex momentum and the $1 billion Firefly Bio oncology acquisition announced June 8, 2026, are replacing Stelara’s lost revenue faster than expected.
- Bear case: Talc litigation still carries a ~$15 billion reserve baseline, Stelara biosimilar erosion continues, and the stock’s 60% run from its 52-week low leaves it technically overbought near-term.
- Income anchor: A 64th consecutive dividend increase to $1.34 per quarter ($5.36 annualized, ~2.2% yield) keeps the payout one of the most reliable in the S&P 500.
What Is Johnson & Johnson? (NYSE: JNJ)
Johnson & Johnson is the world’s largest diversified healthcare company by market value, listed on the NYSE under ticker JNJ and currently valued at roughly $570 billion. Since spinning off its consumer health unit (Kenvue) in 2023, the company operates two segments. Innovative Medicine — about two-thirds of revenue — spans immunology (Tremfya, the new oral IL-23 drug Icotyde), oncology (Darzalex, Carvykti, Tecvayli, and the bladder-cancer system Inlexzo), and neuroscience. MedTech — the remaining third — sells surgical tools, orthopedics, vision products, and fast-growing cardiovascular devices built through acquisitions like Abiomed and Shockwave.
That structure matters for anyone valuing the company in 2026. The company is executing one of the pharma industry’s most-watched patent-cliff transitions: Stelara, once a $10+ billion immunology franchise, is eroding under biosimilar competition, and J&J is backfilling the hole with new launches and bolt-on M&A. The June 8, 2026 agreement to acquire Firefly Bio for $1 billion extends the oncology pipeline into protein-degrader territory. In Q1 2026, Innovative Medicine sales still grew 7.4% and MedTech grew 4.6% — evidence the transition is working. Competitors face their own versions of the same cliff: AbbVie stock price strength after Humira’s patent loss is the playbook J&J is now repeating, while Merck stock price debates center on Keytruda’s 2028 expiry.
Scale is the underappreciated moat here. J&J spends roughly $17 billion a year on R&D, holds a AAA credit rating shared with only one other US company, and generates free cash flow of around $20 billion annually — enough to fund the dividend, litigation reserves, and acquisitions simultaneously without stressing the balance sheet. In surgical robotics, its Ottava platform is the most credible long-term challenger to Intuitive Surgical stock price dominance, giving MedTech an optionality kicker that rarely features in bear models of JNJ stock.
JNJ Stock Recent Performance in 2026
JNJ stock has been one of 2026’s quiet outperformers. Shares traded between $237.05 and $240.93 on June 10 and sit about 5% below the 52-week high of $251.71 — a high reached after a near-uninterrupted climb from the $149.04 low. The roughly 60% trailing-twelve-month gain has crushed the broader pharma group, which spent much of the period weighed down by drug-pricing politics and tariff noise. For a mega-cap that many investors still file under “bond proxy,” a 60% twelve-month gain is a regime change, and it has pulled both momentum funds and dividend-growth money into the same name at the same time.
Three catalysts drove the move. First, earnings: on April 14, 2026, J&J beat Q1 estimates with $24.06 billion in revenue and $2.70 EPS, then raised full-year guidance to ~$100.8 billion — roughly 10% above 2025’s reported total. Second, the pipeline delivered: Icotyde’s April 2026 launch gave J&J the first oral IL-23 inhibitor in psoriasis, Phase 2 JASMINE data showed nipocalimab met its primary endpoint in lupus, and Inlexzo continued its strong bladder-cancer uptake. Third, sentiment followed price — Scotiabank reiterated a Buy on June 9, and Leerink Partners upgraded the stock earlier in the year, citing “strong new drug momentum.” The one wobble came in late April, when the shares fell about 3% in a session on talc-litigation headlines — a reminder that the legal overhang has not disappeared, merely quieted.
The next scheduled catalyst is the Q2 earnings report on July 15, 2026. The Street will focus on three lines: whether Innovative Medicine growth holds above 7% as Stelara comparisons get easier through the year, whether Icotyde’s prescription ramp justifies the launch-year enthusiasm, and whether management nudges the $11.30–$11.50 EPS guide higher for a second consecutive quarter. The setup mirrors April’s: expectations have risen with the price, but guidance was set conservatively enough that the company has cleared every bar it has put up for eight straight quarters. Beyond July, the JASMINE lupus data package moves toward Phase 3 decisions, and the Q3 call is already scheduled for October 13 — a cadence of catalysts that keeps the story moving without requiring any single binary event to land.
JNJ Stock Valuation Analysis
At $239, JNJ stock trades at 22x trailing earnings and about 21x the $11.40 midpoint of 2026 adjusted EPS guidance. That is a premium to its own five-year average (mid-to-high teens) but remains reasonable against large-cap pharma peers posting similar growth, and it is well below high-multiple medtech pure-plays. The market is effectively re-rating J&J from a low-growth defensive toward a mid-single-digit grower with a credible new-product cycle.
| Valuation Metric | JNJ | Context |
|---|---|---|
| Forward P/E | ~21x | Five-year average: mid-to-high teens |
| FY2026 Revenue Guide | ~$100.8B | +5.9% to +6.9% operational growth |
| FY2026 Adjusted EPS | $11.30–$11.50 | Raised after Q1 beat |
| Dividend Yield | ~2.2% | $5.36/yr, 64 straight annual increases |
| DCF Fair-Value Estimates | up to $363 (bull-case DCF) | Bear-case fair value ~$174 |
The wide DCF spread — independent models put bull-case intrinsic value as high as $363 and bear-case fair value near $174 — is really a referendum on two binary variables: whether the new-drug cycle fully offsets Stelara, and whether talc liability stays inside the ~$15 billion reserve. Our base case sits between those poles: at 21x forward earnings with a raised guide, JNJ stock is fairly priced for the pharma business alone, which means the MedTech re-acceleration and pipeline optionality come almost free. Compare that with Medtronic stock price multiples for slower medtech growth and the relative value case becomes clearer.
A sum-of-the-parts lens reinforces the point. Innovative Medicine alone is on pace for roughly $66–$68 billion in 2026 sales; valued at a typical large-pharma multiple, it covers the bulk of today’s $570 billion market cap. That leaves the ~$33 billion MedTech franchise — growing mid-single digits with margin expansion as Abiomed and Shockwave scale — priced at a clear discount to standalone device peers. The dividend adds a valuation floor: at $5.36 per share, the payout consumes less than half of guided EPS, and history shows the shares rarely yield much above 3% for long before income buyers step in. That dynamic effectively capped the 2025 drawdown near $149 and argues against the deep bear-case scenarios absent a litigation shock.
JNJ Dividend and Income Profile
For income investors, JNJ is less a stock than an institution. The 2026 increase to $1.34 per quarter — $5.36 annualized — extended the streak to 64 consecutive years, a record that survived the 2008 financial crisis, the COVID shutdowns, the Kenvue consumer-health spinoff, and every patent cliff since the Kennedy administration. At the $11.40 midpoint of 2026 adjusted EPS guidance, the payout ratio sits near 47% — comfortably below the 60% threshold where dividend growth typically slows — and the company’s roughly $20 billion of annual free cash flow covers the distribution nearly twice over before a dollar of buybacks or M&A.
The balance sheet removes the tail risk that haunts most high-yield equities: J&J is one of only two US corporations holding a AAA credit rating, which means the dividend is effectively senior to nothing and threatened by nothing short of a corporate catastrophe. Historical growth has averaged 5–6% annually over the past decade, so a buyer at today’s ~2.2% yield is plausibly looking at a 3.5–4% yield-on-cost within ten years without reinvestment — and meaningfully more with it. The practical comparison investors should run is against the 10-year Treasury: the bond pays more today, but its coupon never grows and carries no claim on a pharmaceutical pipeline. For portfolios built around rising income streams, that trade-off has favored the equity in every decade since the streak began, which is precisely why the income bid reasserts itself whenever the shares sell off hard enough to push the yield toward 3%.
Bullish and Bearish Analyst Opinions on Johnson & Johnson
Wall Street coverage of JNJ leans constructive but is not unanimous — of roughly 25 analysts, about 12 rate it Strong Buy, 3 Moderate Buy, and 10 Hold, with zero Sells. Here is how the two camps line up:
| The Bull Argument | The Bear Counter |
|---|---|
| New-product cycle: Icotyde and Inlexzo launches are beating early forecasts, feeding straight into higher out-year revenue estimates. | Execution risk: those same higher estimates mean any miss on Tecvayli, Inlexzo, or Tremfya now disappoints against a raised bar. |
| Guidance momentum: FY2026 raised to ~$100.8B revenue and $11.30–$11.50 EPS after a clean Q1 beat. | Stelara erosion: biosimilar competition keeps carving into what was a $10B+ franchise; organic growth must keep outrunning it. |
| Oncology depth: Darzalex strength plus the $1B Firefly Bio deal (June 8, 2026) extend the growth runway. | Talc overhang: an adverse appellate ruling could force reserves “far beyond the current $15 billion baseline.” |
| Income reliability: 64 consecutive dividend hikes; $5.36 annualized payout. | Valuation/timing: at 22x trailing and ~5% off the high, the stock is overbought near-term; bears see fair value near $174 if sentiment turns risk-off. |
Named voices anchor both sides. David Risinger of Leerink Partners upgraded JNJ to Outperform and lifted his target to $265, built explicitly on Icotyde’s launch trajectory. HSBC went further on March 17, 2026, setting the Street-high $280 target. The cautious camp is represented less by Sell ratings than by the ten Hold ratings — firms arguing the optimism is already in the price after the 60% run. Notably, the most bearish published target on record, Leerink’s own $153 from May 2025, was abandoned by the same firm within a year — a measure of how quickly the bullish and bearish analyst opinions on Johnson & Johnson have shifted toward the bulls.
JNJ Stock Analyst Price Targets and Verdict
The target map: HSBC at $280 (Street high), Leerink Partners at $265 (David Risinger, Outperform), MarketBeat’s tracked consensus at $253, and broader aggregator averages between $238 and $253 depending on the analyst pool. Even the conservative end of that range sits at or above the current JNJ stock quote, and the consensus rating is Buy/Moderate Buy across every major aggregator.
Our verdict: Buy — the risk/reward favours bulls. The math is straightforward. Downside to the bear-case fair value (~$174) requires a talc-litigation shock or a multi-product launch failure; upside to $265–$280 requires only that management keeps doing what it did in Q1. A raised $100.8 billion guide, 7.4% Innovative Medicine growth, a 64th dividend increase, and active bolt-on M&A describe a company compounding through its patent cliff, not falling off it. Long-term investors should not wait for a pullback that may never come; those adding new money can size positions gradually given the stock sits near all-time highs. JNJ stock remains a core healthcare holding for 2026.
What would change the call? Three triggers: an adverse appellate talc ruling that forces reserves materially above $15 billion, two consecutive quarters of Innovative Medicine growth below 4%, or Icotyde prescription trends rolling over against Street models. None is visible in the June 2026 data. Until one appears, pullbacks toward the $210–$220 zone — roughly the consensus floor — should be treated as accumulation opportunities rather than warnings.
JNJ Stock Risks to Watch Through 2026
A Buy rating is not a claim that nothing can go wrong, so the risk register deserves its own ledger. Talc remains item one: the ~$15 billion reserve is an estimate, not a ceiling, and an adverse appellate ruling on the Daubert scientific-evidence question could validate plaintiffs’ claims and force a step-change in provisions. The market has lived with this overhang for years, but “priced in” only holds while rulings go the company’s way. Item two is the Stelara erosion curve — biosimilar competition typically steepens in year two as payer formularies switch wholesale, so the 7.4% Innovative Medicine growth printed in Q1 must absorb a larger drag in the back half.
Item three is MedTech competition: pulsed-field ablation has scrambled the electrophysiology market share map, and orthopedics remains a knife-fight with Stryker and Zimmer. Item four is policy — US drug-pricing negotiation rounds continue to expand, and any acceleration of the IRA’s reach into J&J’s top sellers would compress the out-year estimates that current targets rest on. Finally, the M&A cadence itself carries integration risk: Abiomed, Shockwave, V-Wave, and now Firefly Bio arrived within four years, and the deals must keep clearing their cost of capital for the bolt-on strategy to keep earning its premium. None of these risks is new, none is hidden, and none currently shows up in the reported numbers — but a disciplined holder reviews them at every print, because the 21x forward multiple assumes management keeps winning on all five fronts at once.
How to Trade JNJ Stock via MEXC
MEXC users can invest in real Johnson & Johnson shares through RealStocks — MEXC’s US stock offering operated in collaboration with licensed brokers. Unlike synthetic products, RealStocks orders correspond to actual US-listed JNJ equity: you fund the position in USDT, own genuine share exposure, and trade during regular US market hours with low fees and deep liquidity, all without opening a separate US brokerage account. Visit the JNJ stock trading page on MEXC, search for the ticker, and place a buy order the same way you would a spot crypto trade. For a dividend compounder like Johnson & Johnson, that direct ownership route is the cleanest way to put the thesis above into practice. The practical steps: complete KYC verification, deposit or convert USDT, navigate to the RealStocks section, and set either a market or limit order — useful if you prefer to stage entries on dips toward the $220 consensus-floor zone discussed above.
JNJ Stock FAQs
Is JNJ a good stock to buy in 2026?
We rate JNJ stock a Buy. Full-year guidance was raised to ~$100.8 billion in revenue, new launches like Icotyde are offsetting Stelara’s decline, and consensus price targets ($238–$253, with a $280 high) sit at or above the ~$239 share price. The main caveat is timing: the stock has rallied roughly 60% from its 52-week low, so near-term consolidation would be normal.
What are the bullish and bearish analyst opinions on Johnson & Johnson?
Bulls — including Leerink’s David Risinger ($265) and HSBC ($280) — point to the new-drug cycle, raised 2026 guidance, and oncology M&A. Bears, mostly expressed through Hold ratings rather than Sells, flag Stelara biosimilar erosion, execution risk on elevated estimates, and talc litigation that could exceed the ~$15 billion reserve. The current split is roughly 15 Buys to 10 Holds, with no Sell ratings.
What is the JNJ stock price target for 2026?
It depends on which analyst pool you track: aggregator consensus runs from $238 to $253, MarketBeat’s tracked average is $253.04, and the published range spans $210 (median of one 32-analyst sample) up to HSBC’s $280 Street high. Most targets imply mid-single-digit to high-teens upside from ~$239.
Does Johnson & Johnson pay a dividend?
Yes — and few companies match its record. J&J raised its quarterly dividend 3.1% to $1.34 per share in 2026 ($5.36 annualized, ~2.2% yield at current prices), marking the 64th consecutive year of increases and keeping its Dividend King status intact.
What did Johnson & Johnson buy in June 2026?
On June 8, 2026, J&J agreed to acquire Firefly Bio for $1 billion to expand its oncology pipeline. Here’s the nuance: at less than 0.2% of J&J’s market cap the deal is financially trivial, but strategically it signals management will keep using bolt-on M&A — as it did with Abiomed and Shockwave in devices — to compound through patent expiries, an approach peers like Stryker stock price watchers know well from the medtech consolidation race.
—Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.